Table 2. Open in new tab Characteristics...

	Outcome of Prior Treatment
Patients	44	39.3	31	27.7	37	33		112	100
Prior treatment							.569
LED/SOF	26	59.1	15	48.4	22	59.5		63	56.2
SOF/VEL	10	22.7	6	19.4	12	32.4	28	24.9
GLE/PIB	2	4.5	2	6.5	1	2.7	5	4.5
SOF + RIB	1	2.3	3	9.7	1	2.7	5	4.5
SOF/DAC	1	2.3	1	3.2	0	0.0	2	1.8
LED/SOF + RIB	2	4.5	0	0.0	0	0.0	2	1.8
ELB/GZP	0	0.0	1	3.2	0	0.0	1	0.9
SOF/SIM	0	0.0	1	3.2	0	0.0	1	0.9
OMB/PRT/DAS/r + RIB	0	0.0	1	3.2	0	0.0	1	0.9
Boceprevir + INF + RIB	0	0.0	0	0.0	1	2.7	1	0.9
Telaprevir + INF + RIB	1	2.3	0	0.0	0	0.0	1	0.9
Unknown	1	2.3	1	3.2	0	0.0	2	1.8
Prior genotype							.065
1a	21	47.7	15	48.4	27	73.0		63	56.2
1b	7	15.9	5	16.1	2	5.4	14	12.5
2a	2	4.5	1	3.2	0	0.0	3	2.7
2b	1	2.3	2	6.5	0	0.0	3	2.7
3	5	11.4	6	19.4	5	13.5	16	14.3
4	1	2.3	1	3.2	2	5.4	4	3.6
6	0	0.0	1	3.2	0	0.0	1	0.0
Unknown	7	15.9	0	0.0	1	2.7	8	7.1
Resistance testing^a	0	0.0	22	71.0	24	64.9	<.001	46	41.1
Current genotype							.203
1a	23	52.3	15	48.4	27	73.0		65	58.0
1b	3	6.8	5	16.1	2	5.4	10	8.9
2	6	13.6	3	9.7	0	0.0	9	8.1
3	10	22.7	6	19.4	6	16.2	22	19.6
4	1	2.3	1	3.2	2	5.4	4	3.6
6	1	2.3	1	3.2	0	0.0	2	1.8
Current regimen							<.001
First-line	41	93.2	4	12.9	18	48.6		63	56.2
Rescue	3	6.8	27	87.1	19	51.4	49	43.8
Current treatment outcome							.015
SVR12	33	75.0	28	90.3	22	59.5		83	74.1
Failure	5	11.4	1	3.2	2	5.4	8	7.1
Indeterminate	6	13.6	2	6.5	13	35.1	21	18.8

Outcome of Prior Treatment

SVR12

Failure

Indeterminate

Total

Variable

No.

P Value

No.

Patients

39.3

27.7

112

100

Prior treatment

.569

LED/SOF

59.1

48.4

59.5

56.2

SOF/VEL

22.7

19.4

32.4

24.9

GLE/PIB

4.5

6.5

2.7

4.5

SOF + RIB

2.3

9.7

2.7

4.5

SOF/DAC

2.3

3.2

0.0

1.8

LED/SOF + RIB

4.5

0.0

1.8

ELB/GZP

0.0

3.2

0.0

0.9

SOF/SIM

0.0

3.2

0.0

0.9

OMB/PRT/DAS/r + RIB

0.0

3.2

0.0

0.9

Boceprevir + INF + RIB

0.0

2.7

0.9

Telaprevir + INF + RIB

2.3

0.0

0.9

Unknown

2.3

3.2

0.0

1.8

Prior genotype

.065

47.7

48.4

73.0

56.2

15.9

16.1

5.4

12.5

4.5

3.2

0.0

2.7

2.3

6.5

0.0

2.7

11.4

19.4

13.5

14.3

2.3

3.2

5.4

3.6

0.0

3.2

0.0

Unknown

15.9

0.0

2.7

7.1

Resistance testing^a

0.0

71.0

64.9

<.001

41.1

Current genotype

.203

52.3

48.4

73.0

58.0

6.8

16.1

5.4

8.9

13.6

9.7

0.0

8.1

22.7

19.4

16.2

19.6

2.3

3.2

5.4

3.6

2.3

3.2

0.0

1.8

Current regimen

<.001

First-line

93.2

12.9

48.6

56.2

Rescue

6.8

87.1

51.4

43.8

Current treatment outcome

.015

SVR12

75.0

90.3

59.5

74.1

Failure

11.4

3.2

5.4

7.1

Indeterminate

13.6

6.5

35.1

18.8

	Outcome of Prior Treatment
Patients	44	39.3	31	27.7	37	33		112	100
Prior treatment							.569
LED/SOF	26	59.1	15	48.4	22	59.5		63	56.2
SOF/VEL	10	22.7	6	19.4	12	32.4	28	24.9
GLE/PIB	2	4.5	2	6.5	1	2.7	5	4.5
SOF + RIB	1	2.3	3	9.7	1	2.7	5	4.5
SOF/DAC	1	2.3	1	3.2	0	0.0	2	1.8
LED/SOF + RIB	2	4.5	0	0.0	0	0.0	2	1.8
ELB/GZP	0	0.0	1	3.2	0	0.0	1	0.9
SOF/SIM	0	0.0	1	3.2	0	0.0	1	0.9
OMB/PRT/DAS/r + RIB	0	0.0	1	3.2	0	0.0	1	0.9
Boceprevir + INF + RIB	0	0.0	0	0.0	1	2.7	1	0.9
Telaprevir + INF + RIB	1	2.3	0	0.0	0	0.0	1	0.9
Unknown	1	2.3	1	3.2	0	0.0	2	1.8
Prior genotype							.065
1a	21	47.7	15	48.4	27	73.0		63	56.2
1b	7	15.9	5	16.1	2	5.4	14	12.5
2a	2	4.5	1	3.2	0	0.0	3	2.7
2b	1	2.3	2	6.5	0	0.0	3	2.7
3	5	11.4	6	19.4	5	13.5	16	14.3
4	1	2.3	1	3.2	2	5.4	4	3.6
6	0	0.0	1	3.2	0	0.0	1	0.0
Unknown	7	15.9	0	0.0	1	2.7	8	7.1
Resistance testing^a	0	0.0	22	71.0	24	64.9	<.001	46	41.1
Current genotype							.203
1a	23	52.3	15	48.4	27	73.0		65	58.0
1b	3	6.8	5	16.1	2	5.4	10	8.9
2	6	13.6	3	9.7	0	0.0	9	8.1
3	10	22.7	6	19.4	6	16.2	22	19.6
4	1	2.3	1	3.2	2	5.4	4	3.6
6	1	2.3	1	3.2	0	0.0	2	1.8
Current regimen							<.001
First-line	41	93.2	4	12.9	18	48.6		63	56.2
Rescue	3	6.8	27	87.1	19	51.4	49	43.8
Current treatment outcome							.015
SVR12	33	75.0	28	90.3	22	59.5		83	74.1
Failure	5	11.4	1	3.2	2	5.4	8	7.1
Indeterminate	6	13.6	2	6.5	13	35.1	21	18.8

Table 2.

Open in new tab

Characteristics and Outcomes of Prior and Current Direct Antiviral Regimens Stratified by Outcomes of Prior Treatment

	Outcome of Prior Treatment
	SVR12		Failure		Indeterminate			Total
Variable	No.	%	No.	%	No.	%	P Value	No.	%
Patients	44	39.3	31	27.7	37	33		112	100
Prior treatment							.569
LED/SOF	26	59.1	15	48.4	22	59.5		63	56.2
SOF/VEL	10	22.7	6	19.4	12	32.4		28	24.9
GLE/PIB	2	4.5	2	6.5	1	2.7		5	4.5
SOF + RIB	1	2.3	3	9.7	1	2.7		5	4.5
SOF/DAC	1	2.3	1	3.2	0	0.0		2	1.8
LED/SOF + RIB	2	4.5	0	0.0	0	0.0		2	1.8
ELB/GZP	0	0.0	1	3.2	0	0.0		1	0.9
SOF/SIM	0	0.0	1	3.2	0	0.0		1	0.9
OMB/PRT/DAS/r + RIB	0	0.0	1	3.2	0	0.0		1	0.9
Boceprevir + INF + RIB	0	0.0	0	0.0	1	2.7		1	0.9
Telaprevir + INF + RIB	1	2.3	0	0.0	0	0.0		1	0.9
Unknown	1	2.3	1	3.2	0	0.0		2	1.8
Prior genotype							.065
1a	21	47.7	15	48.4	27	73.0		63	56.2
1b	7	15.9	5	16.1	2	5.4		14	12.5
2a	2	4.5	1	3.2	0	0.0		3	2.7
2b	1	2.3	2	6.5	0	0.0		3	2.7
3	5	11.4	6	19.4	5	13.5		16	14.3
4	1	2.3	1	3.2	2	5.4		4	3.6
6	0	0.0	1	3.2	0	0.0		1	0.0
Unknown	7	15.9	0	0.0	1	2.7		8	7.1
Resistance testing^a	0	0.0	22	71.0	24	64.9	<.001	46	41.1
Current genotype							.203
1a	23	52.3	15	48.4	27	73.0		65	58.0
1b	3	6.8	5	16.1	2	5.4		10	8.9
2	6	13.6	3	9.7	0	0.0		9	8.1
3	10	22.7	6	19.4	6	16.2		22	19.6
4	1	2.3	1	3.2	2	5.4		4	3.6
6	1	2.3	1	3.2	0	0.0		2	1.8
Current regimen							<.001
First-line	41	93.2	4	12.9	18	48.6		63	56.2
Rescue	3	6.8	27	87.1	19	51.4		49	43.8
Current treatment outcome							.015
SVR12	33	75.0	28	90.3	22	59.5		83	74.1
Failure	5	11.4	1	3.2	2	5.4		8	7.1
Indeterminate	6	13.6	2	6.5	13	35.1		21	18.8

	Outcome of Prior Treatment
	SVR12		Failure		Indeterminate			Total
Variable	No.	%	No.	%	No.	%	P Value	No.	%
Patients	44	39.3	31	27.7	37	33		112	100
Prior treatment							.569
LED/SOF	26	59.1	15	48.4	22	59.5		63	56.2
SOF/VEL	10	22.7	6	19.4	12	32.4		28	24.9
GLE/PIB	2	4.5	2	6.5	1	2.7		5	4.5
SOF + RIB	1	2.3	3	9.7	1	2.7		5	4.5
SOF/DAC	1	2.3	1	3.2	0	0.0		2	1.8
LED/SOF + RIB	2	4.5	0	0.0	0	0.0		2	1.8
ELB/GZP	0	0.0	1	3.2	0	0.0		1	0.9
SOF/SIM	0	0.0	1	3.2	0	0.0		1	0.9
OMB/PRT/DAS/r + RIB	0	0.0	1	3.2	0	0.0		1	0.9
Boceprevir + INF + RIB	0	0.0	0	0.0	1	2.7		1	0.9
Telaprevir + INF + RIB	1	2.3	0	0.0	0	0.0		1	0.9
Unknown	1	2.3	1	3.2	0	0.0		2	1.8
Prior genotype							.065
1a	21	47.7	15	48.4	27	73.0		63	56.2
1b	7	15.9	5	16.1	2	5.4		14	12.5
2a	2	4.5	1	3.2	0	0.0		3	2.7
2b	1	2.3	2	6.5	0	0.0		3	2.7
3	5	11.4	6	19.4	5	13.5		16	14.3
4	1	2.3	1	3.2	2	5.4		4	3.6
6	0	0.0	1	3.2	0	0.0		1	0.0
Unknown	7	15.9	0	0.0	1	2.7		8	7.1
Resistance testing^a	0	0.0	22	71.0	24	64.9	<.001	46	41.1
Current genotype							.203
1a	23	52.3	15	48.4	27	73.0		65	58.0
1b	3	6.8	5	16.1	2	5.4		10	8.9
2	6	13.6	3	9.7	0	0.0		9	8.1
3	10	22.7	6	19.4	6	16.2		22	19.6
4	1	2.3	1	3.2	2	5.4		4	3.6
6	1	2.3	1	3.2	0	0.0		2	1.8
Current regimen							<.001
First-line	41	93.2	4	12.9	18	48.6		63	56.2
Rescue	3	6.8	27	87.1	19	51.4		49	43.8
Current treatment outcome							.015
SVR12	33	75.0	28	90.3	22	59.5		83	74.1
Failure	5	11.4	1	3.2	2	5.4		8	7.1
Indeterminate	6	13.6	2	6.5	13	35.1		21	18.8

Abbreviations: DAC, daclatasvir; DAS, dasabuvir; ELB, elbasvir; GLE, glecaprevir; GZP, grazoprevir; INF, interferon; LED, ledipasvir; OMB, ombitasvir; PIB, pibrentasvir; PRT, paritaprevir; r, ritonavir; RIB, ribavirin; SIM, simeprevir; SOF, sofosbuvir; SVR12, sustained virologic response at 12 weeks; VEL, velpatasvir.

^aDuring current treatment.

This Feature Is Available To Subscribers Only